TRUFF (Rhelion Life Sciences) Intrinsic Value: Projected FCF: $-0.02 (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rhelion Life Sciences Intrinsic Value: Projected FCF?

Rhelion Life Sciences TRUFF -2.53% Intrinsic Value: Projected FCF is $-0.02 as of Sep. 21, 2026. The stock has 6 warning signs investors should review. Among 635 Drug Manufacturers companies, Rhelion Life Sciences ranks worse than 157480.16% on this metric.

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2026-09-21), Rhelion Life Sciences's Intrinsic Value: Projected FCF is $-0.02. The stock price of Rhelion Life Sciences is $0.0231. Therefore, Rhelion Life Sciences's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Rhelion Life Sciences's Intrinsic Value: Projected FCF or its related term are showing as below:

TRUFF's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.54
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Rhelion Life Sciences  (OTCPK:TRUFF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Rhelion Life Sciences's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0231/-0.031829063007791
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhelion Life Sciences Intrinsic Value: Projected FCF Related Terms


Rhelion Life Sciences Intrinsic Value: Projected FCF Historical Data

* Premium members only.

The historical data trend for Rhelion Life Sciences's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhelion Life Sciences Intrinsic Value: Projected FCF Chart

Rhelion Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rhelion Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TRUFF vs ZTS: Intrinsic Value: Projected FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhelion Life Sciences Price-to-Projected-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Rhelion Life Sciences's Price-to-Projected-FCF falls into.



Rhelion Life Sciences Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Rhelion Life Sciences's Free Cash Flow(6 year avg) = $-2.96.

Rhelion Life Sciences's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jun26)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-2.9574576+13.254770748899*0.8)/551.452601
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Intrinsic Value: Projected FCF of $-0.02 mean?
Rhelion Life Sciences (TRUFF) has a Intrinsic Value: Projected FCF of $-0.02 as of Sep. 21, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Rhelion Life Sciences and its competitors. According to the industry distribution chart, Rhelion Life Sciences ranks #999999 out of 635 companies in the Drug Manufacturers industry.
Is Rhelion Life Sciences' Intrinsic Value: Projected FCF too high?
Rhelion Life Sciences' current Intrinsic Value: Projected FCF is $-0.02. Based on the distribution chart, Rhelion Life Sciences ranks #999999 out of 635 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Rhelion Life Sciences' Intrinsic Value: Projected FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Rhelion Life Sciences ranks #999999 out of 635 companies for Intrinsic Value: Projected FCF. This places Rhelion Life Sciences in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.54, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Rhelion Life Sciences and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhelion Life Sciences's current Intrinsic Value: Projected FCF is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (TRUFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 15.5% above its estimated fair value. The current Intrinsic Value: Projected FCF is $-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Rhelion Life Sciences (TRUFF), the current Intrinsic Value: Projected FCF is $-0.02 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhelion Life Sciences Business Description

Other Exchanges 4YX:GermanyTRIP:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.